WHO ICTRP trial
A Phase iii Study for Evaluating Jaktinib vs Hydroxycarbamide in Subjects with…
ChiCTR2100047040 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100047040 |
|---|---|
| Public title | A Phase iii Study for Evaluating Jaktinib vs Hydroxycarbamide in Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis |
| Scientific title | A Phase iii, Randomized, Double-blind controlled study for Evaluating Jaktinib vs Hydroxycarbamide in Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis |
| Primary sponsor | The First Affiliated Hospital of Medical School of Zhejiang University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 3 |
| Countries | China |
| Conditions | Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post- essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
| Interventions | Experimental group:Jaktinib, 100mg, bid;Control group:Hydroxycarbamide, 0.5g,bid |
| Registration date | Jun 7, 2021 |
| Target size | Experimental group:70;Control group:35 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: